Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:59 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 1,851 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

NCT01923207
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Nov 3, 2026, 6:59 PM EST
Completed Phase 3 Interventional Results available

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

NCT01949311
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Nov 3, 2026, 6:59 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

NCT05486208
View directory record Official record
Conditions
Healthy, Dermatitis, Atopic
Interventions
LY3844583, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 6:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Actis Total Hip System 2 Year Follow-up

NCT02783274
View directory record Official record
Conditions
Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congenital Hip Dysplasia, Avascular Necrosis of the Femoral Head, Acute Traumatic Fracture of the Femoral Head or Neck, Certain Cases of Ankylosis, Non-union of Femoral Neck Fractures, Certain High Sub-Capital & Femoral Neck Fractures in Elderly
Interventions
Actis Total Hip System
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
21 Years and older
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
9
States / cities
Louisville, Kentucky • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Nov 3, 2026, 6:59 PM EST
Completed Phase 2 Interventional

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

NCT05432596
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Nov 3, 2026, 6:59 PM EST
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT04250350
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Nov 3, 2026, 6:59 PM EST
Recruiting Phase 4 Interventional

Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

NCT07560618
View directory record Official record
Conditions
ITCH, Atopic Dermatitis
Interventions
Roflumilast Cream 0.15%
Drug
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 3, 2026, 6:59 PM EST
Completed Phase 3 Interventional Results available

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

NCT01386658
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
icatibant
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Shreveport, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Nov 3, 2026, 6:59 PM EST
Completed No phase listed Observational Results available

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

NCT01059526
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
40
States / cities
Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Nov 3, 2026, 6:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Korean Translation and Validation of the K-HEPI in NYC

NCT05544578
View directory record Official record
Conditions
Disaster, Vulnerable Populations
Interventions
Nurses Taking On Readiness Measures (N- TORM)
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Nov 3, 2026, 6:59 PM EST
Terminated No phase listed Observational

Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA

NCT01733615
View directory record Official record
Conditions
Mucopolysaccharidosis Type IVA
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Nov 3, 2026, 6:59 PM EST
Completed Phase 1 Interventional

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07336940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294 Capsule
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Fremont, California • Louisville, Kentucky • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 3, 2026, 6:59 PM EST
Completed Phase 2 Interventional Results available

A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

NCT05569252
View directory record Official record
Conditions
Pseudoxanthoma Elasticum
Interventions
DS-1211b, Placebo
Drug · Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Bethesda, Maryland • North Dartmouth, Massachusetts • Secaucus, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Nov 3, 2026, 6:59 PM EST
Completed Not applicable Interventional

Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients

NCT03796052
View directory record Official record
Conditions
Ichthyosis, Pruritus
Interventions
Avena Sativa Skincare Regimen
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Nov 3, 2026, 6:59 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Cancer of the Pancreas Screening Study (CAPS 3)

NCT00438906
View directory record Official record
Conditions
Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions
Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Nov 3, 2026, 6:59 PM EST
Completed Not applicable Interventional Results available

Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions

NCT05097157
View directory record Official record
Conditions
Wrinkle, Fine Lines, Crepey Skin, Acne Scars, Acne, Enlarged Pores, Stretch Marks, Loose Skin
Interventions
Potenza
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Sacramento, California • Hunt Valley, Maryland • Westford, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Nov 3, 2026, 6:59 PM EST
Recruiting Phase 1 Interventional

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

NCT02254863
View directory record Official record
Conditions
Adrenoleukodystrophy, Batten Disease, Mucopolysaccharidosis II, Leukodystrophy, Globoid Cell, Leukodystrophy, Metachromatic, Neimann Pick Disease, Pelizaeus-Merzbacher Disease, Sandhoff Disease, Tay-Sachs Disease, Brain Diseases, Metabolic, Inborn, Alpha-Mannosidosis, Sanfilippo Mucopolysaccharidoses
Interventions
DUOC-01
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
1 Week to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 6:59 PM EST
Completed Phase 3 Interventional

Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation

NCT00003883
View directory record Official record
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Nov 3, 2026, 6:59 PM EST
Recruiting Phase 2Phase 3 Interventional

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05789056
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003, 4% Lotion
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 3, 2026, 6:59 PM EST
Not yet recruiting Not applicable Interventional

COG+OT Telerehabilitation for Adults With Subjective Cognitive Complaints

NCT07743229
View directory record Official record
Conditions
Subjective Cognitive Complaints, Ehlers-Danlos Syndrome, Cognitive Dysfunction
Interventions
COG+OT Telerehabilitation
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 3, 2026, 6:59 PM EST
Completed Phase 1 Interventional

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT03050151
View directory record Official record
Conditions
Atopic Disorders, Eczema, Atopic
Interventions
Dupilumab, Auto-injector Device, Prefilled syringe
Drug · Device
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Nov 3, 2026, 6:59 PM EST
Not yet recruiting No phase listed Observational

Natural History to Assess Disease in Patients With MPS IIIC

NCT07712003
View directory record Official record
Conditions
Sanfilippo Syndrome Type C, Mucopolysaccharidosis (MPS) IIIC
Interventions
Not listed
Lead sponsor
Phoenix Nest
Industry
Eligibility
1 Year to 25 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 3, 2026, 6:59 PM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy

NCT03089476
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Food Allergy
Interventions
Evaluating atopy in infants, Evaluating TEWL and STS in adults
Other
Lead sponsor
National Jewish Health
Other
Eligibility
34 Weeks to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Nov 3, 2026, 6:59 PM EST
Terminated Phase 4 Interventional

Dupilumab De-escalation in Pediatric Atopic Dermatitis

NCT06116526
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 6:59 PM EST